donepezil has been researched along with sildenafil in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sen, S; Sinha, N | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Guo, D; Jiang, YR; Zhao, XJ; Zhou, LY; Zhu, Y | 1 |
| Chen, JW; Chen, Y; Chen, YP; Geng, H; Li, Z; Luo, HB; Tian, YJ; Wang, Y; Wu, Y; Yu, YF; Zhang, C; Zhang, P; Zhang, T; Zhou, Q | 1 |
| Dong, YH; Huang, XF; Ke, HM; Song, GQ; Wang, JH; Xu, DF | 1 |
1 review(s) available for donepezil and sildenafil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for donepezil and sildenafil
| Article | Year |
|---|---|
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Phosphodiesterase Inhibitors; Structure-Activity Relationship | 2017 |
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Binding Sites; Catalytic Domain; Dementia, Vascular; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Maze Learning; Mice; Molecular Docking Simulation; Phosphodiesterase Inhibitors; Protein Isoforms; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2019 |
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Antagonists; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Indole Alkaloids; Mice; Models, Molecular; Molecular Structure; Morris Water Maze Test; Phosphodiesterase 5 Inhibitors; Protein Conformation; Quinazolines; Scopolamine | 2020 |